UK institute confirms narrow guidance for infliximab in colitis
This article was originally published in Scrip
Schering-Plough's Remicade (infliximab, licensed from Johnson & Johnson) has been recommended for treating exacerbations of severely active ulcerative colitis in the national health service in England and Wales, but only in patients in whom ciclosporin is contraindicated. The National Institute for health and Clinical Exellencehas published guidance confirming its draft recommendations on the product in this indication (Scrip Online, August 13th, 2008). Local health authorities normally have three months to implement NICE guidance in clinical practice after it has been published.
You may also be interested in...
Local health authorities in Coventry, UK, say it is most unlikely that vaccination with GlaxoSmithKline's Cervarix (human papillomavirus vaccine) was the cause of the death of a 14-year-old schoolgirl on September 28th.
Patents on Janssen-Cilag's (Johnson & Johnson) anti-epileptic Topamax/Epitomax (topiramate) expired in many European countries on September 25th, and generics companies are launching their own versions quickly.
Lilly's Alimta (pemetrexed) has been recommended as a first-line treatment for some patients in England and Wales with non-small cell lung cancer (NSCLC) in binding guidance for the national health service.